Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor

Clinical and Experimental Hypertension

Volumn 18, Issue 5, 1996, Pages 625-636

  Chen, Sufang ^a   Kashiwabara, Hideyuki ^a   Kosegawa, Itaru ^a   Ishii, Jun ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

angiotensin II receptor antagonist; angiotensin converting enzyme inhibitor; bradykinin receptor antagonist; fructose fed rats; insulin resistance

Indexed keywords

ALACEPRIL; BRADYKININ; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029894017     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969609081771     Document Type: Article

References (24)

1. Modan M, Halkin H, Almog S, Lusky A, Eskol A, Shefi M, Shirit A, Fuchs L: A link between hypertension, obesity and glucose intolerence. J Clin Invest 1985; 75: 809-817.
2. Reaven GM: Role of insulin in human disease. Diabetes 1988; 38: 1595-1607.
3. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico M, Oleggini M, Gadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
4. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ: The effects of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55: 845-855.
5. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L: Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-225.
6. Rett K, Lotz N, Wicklmayr M, Fink E, Jauch KW, Gunther B, Dierze G. Verbesserte Insulinwirkung durch ACE-Hemmung beim Type-II-Diabetiker. Dtsch med Wschr 1988; 113: 243-249.
7. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
8. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990; 13: 1109-1111.
9. Santoro D, Natali A, Palmbo C, Brandi LS, Piatti M, Ghione S, Ferrannini E. Effects of chronic angiotensin converting enzyme inhib.tion on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 1992; 20: 181-191.
10. 8] bradykinin). Eur J Pharmacol 1992; 210: 115-120.
11. Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K. Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new non-peptide All antagonist. Biochem Pharmacol 1993; 46: 311-318.
12. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-Ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid(CV-11974), and its prodrug, (±)-1-(Cyclohexyloxycarbonyloxy)-ethyl 2-Ethoxy-1 -[[2±-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1 H-benzimidazole-7-carboxylate(TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
13. Mondon CE, Reaven GM: Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metabolism 1988; 37: 303-305.
14. Hwang I-S, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512-516.
15. 2-receptor blockade facilitates deoxycorticosterone-salt hypertension. Hypertension 1993; 21: 980-984.
16. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gravas I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 1986; 8: 971-974.
17. Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist FOE 140 abolishes the antihypertensive effect of ramipril. Br J Pharmacol 1992; 105: 771-772.
18. Dietze G. Modulation of the action of insulin in relation to the energy state in skeletal muscle tissue: possible involvement of kinins and prostaglandins. Mol Cell Endocrinol 1982; 25: 127-149.
19. Hartl WH, Jauch K-W, Herndon DM, Cohnert TU, Schildberg FW. Effect of low-dose bradykinin on glucose metabolism and nitrogen balance in surgical patients. Lancet 1990; 335: 69-71.
20. Dietze G, Maerker E, Lodri C, Schifman R, Wickimayr M, Geiger R, Fink E, Boettger I, Fritz H, Melinert H. Possible involvement of kinins in muscle energy metabolism. Adv Exp Med Biol 1984; 167: 63-71.
21. Jauch KW, Hartl W, Guenther B, Wicklmayer M, Rett K, Dietz G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1987; 17: 448-454.
22. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y, Kurumatani H, Kobayashi F, Kanmatsuse K, Kajiwara N. Kinins contribute to the improvement of insu-in sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994; 23: 450-455.
23. Shimamoto K, Matsuda K, Takizawa H, Higashiura K, Ura N, limura O. Effects of an angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructose-fed rats. Blood Pressure 1994; 3 (suppl 5) : 113-116.
24. Kobayashi R, Nagano M, Nakamura F, Higaki J, Fujioka Y, Ikegami Mikami H, Kawaguchi N, Onishi S, Ogihara T. Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats. Hypertension 1993; 21: 1051-1055.